Alpha Teknova (TKNO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$43.7M

Revenue (quarter)

$12.2M

Revenue growth (year over year)

+18.45%

Gross profit (trailing twelve months)

$15.1M

Gross margin

34.60%

Net income (trailing twelve months)

−$16.8M

Net income (quarter)

−$3.2M

Net income growth (year over year)

+11.20%

Net margin

−38.37%

Return on equity

−24.19%

EPS (trailing twelve months)

−$0.31

Book value per share

$1.17

P/E (trailing twelve months)

—

Price to book

6.68

Debt to assets

34.71%

Payout ratio

—

Dividend yield

—

Company profile

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

• Is Alpha Teknova (TKNO) profitable?

  No. Alpha Teknova reported a net loss of $16.8M over the trailing twelve months.

• How much revenue does Alpha Teknova (TKNO) make?

  Alpha Teknova generated $43.7M in revenue over the trailing twelve months, up 18.45% year over year.

• How do I buy stock in Alpha Teknova (TKNO)?

  TKNO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.